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Objective. We aimed to compare a chemiluminescent immunoassay (CIA, QUANTA Flash) on BIO-FLASH with a multiplex flow
immunoassay (MFI) on BioPlex 2200 for the detection of antibodies to Ro60, Ro52, and SS-B. Methods. The study included 241
samples, from patients suffering from systemic autoimmune diseases (𝑛 = 108) as well as disease controls (𝑛 = 133). All samples
were tested for anti-Ro52, anti-Ro60, and anti-SS-B (La) antibodies on QUANTA Flash (INOVA Diagnostics, San Diego, USA)
and BioPlex 2200 (Bio-Rad Laboratories Inc., Hercules, USA). Discrepant samples were tested by two independent methods:
BlueDot/ANA and QUANTRIX Microarray (both D-tek, Belgium). Results. The overall qualitative agreements were 95.4% (95%
confidence interval, CI 92.0–97.7%) for anti-Ro52, 98.8% (95% CI 96.4–99.7%) for anti-Ro60, and 91.7% (95% CI 87.5–94.9%) for
anti-SS-B antibodies.There were 34 discrepant samples among all assays (20 anti-SS-B, 11 anti-Ro52, 3 anti-Ro60). 30/33 of retested
samples (by D-tek dot blot) agreed with the QUANTA Flash results. Similar findings were obtained with QUANTRIX Microarray
kit. Conclusion. QUANTA Flash and BioPlex 2200 show good qualitative agreement. The clinical performances were similar for
anti-Ro52 and anti-Ro60 autoantibodies while differences were observed for anti-SS-B (La) antibodies.
1. Introduction
Autoantibodies targeting extractable nuclear antigens (ENA)
are hallmarks in the diagnosis of systemic autoimmune
rheumatic disease (SARD) such as systemic lupus erythe-
matosus (SLE), Sjo¨gren’s syndrome (SjS), systemic sclerosis
(SSc), polymyositis/dermatomyositis (PM/DM), and mixed
connective tissue disease (MCTD). In addition, anti-ENA
antibodies can be detected in undifferentiated connective
tissue disease (UCTD) [1]. The primary antigenic targets of
anti-ENA antibodies are U1-ribonucleoproteins (RNP), Sm
(Smith antigen) [2], Scl-70 (topoisomerase I) [3], Jo-1, Ro60
(SS-A) [4], Ro52 (TRIM21) [4], and SS-B (La) [1]. Not all
of those antibodies are specific for a particular disease but
are useful to help ruling in or out SARD [1]. Among the
most common autoantibodies are those to Ro52, Ro60 and
SS-B [1]. Historically, anti-Ro52 and anti-Ro60 antibodies
combined have been detected and reported [4]. However,
recent data suggested that both the cellular function of the
two proteins and the disease association of anti-Ro52 and
anti-Ro60 antibodies are significantly different [1, 4, 5]. In
addition, about 20% of those antibodies can be missed when
tested using a blend of the two antigens [4]. Besides the
diagnostic value of antibodies to Ro52, Ro60, and SS-B, it
has been shown that those antibody specificities can precede
the clinical onset of SLE for many years [6]. In addition,
antibodies to the three antigens characterize a subpopulation
of SLE patients that are clinically different from other SLE
patients [7]. Several assays have been developed and used
for the detection of anti-ENA antibodies including ELISA,
line immunoassays (LIA) [8], multiplex flow immunoassay
(MFI) mostly referred to as addressable laser bead assays
(ALBIA) [9–12] and protein arrays [13]. In recent years,
the chemiluminescence technology, which has been used
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for clinical chemistry for more than 10 years, has been
applied for autoantibody testing [14, 15]. The objective of
the present study was to analyze the performance of novel
chemiluminescent immunoassays (CIA, QUANTA Flash) on
BIO-FLASH, a rapid-response chemiluminescent analyzer in
comparison with multiplex flow immunoassay on BioPlex
2200 system for the detection of antibodies to Ro60, Ro52,
and SS-B. Additionally, the clinical utility of antibody titer
and multiple positivity [16] were analyzed.
2. Materials and Methods
2.1. Sera. The study included 241 samples from patients
suffering from SARD (𝑛 = 108) as well as disease controls
(𝑛 = 133). All samples were tested for anti-Ro52, anti-
Ro60, and anti-SS-B antibodies by QUANTA Flash (INOVA
Diagnostics, San Diego, USA) and BioPlex 2200 (Bio-Rad
Laboratories Inc., Hercules, USA). Discrepant samples were
tested by two independent methods: BlueDot/ANA and
QUANTRIX Microarray (both D-tek, Belgium). The diag-
noses were established as described before [17] or according
to the standard disease criteria.
This study meets and is in compliance with all ethical
standards in medicine, and informed consent was obtained
from all patients according to the Declaration of Helsinki.
2.2. QUANTA Flash Assays. The QUANTA Flash assays
(INOVA Diagnostics Inc., San Diego, CA, USA) are novel
CIAs that are used on the BIO-FLASH instrument (Biokit
S.A., Barcelona, Spain), fitted with a luminometer, as well as
all the hardware and liquid handling accessories necessary
to fully automate the assay. The principle of the BIO-FLASH
system has recently been described [14, 15]. The QUANTA
Flash assays for this study were developed using recombi-
nant antigens (INOVA Diagnostics, see Table 1) coated onto
paramagnetic beads. Prior to use, the lyophilized beads are
resuspended using the resuspension buffer. A patient serum
sample is prediluted with the BIO-FLASH sample buffer
in a small disposable plastic cuvette. Small amounts of the
diluted patient serum, the beads, and the assay buffer are all
combined into a second cuvette, mixed, and then incubated
for 9.5minutes at 37∘C.Themagnetized beads are sedimented
using a strong magnet in the washing station and washed
several times followed by addition of isoluminol conjugated
anti-human IgG and again incubated 9.5 minutes at 37∘C.
Themagnetized beads are sedimented andwashed repeatedly.
The isoluminol conjugate is oxidizedwhen sodiumhydroxide
solution and peroxide solutions (“Triggers”) are added to the
cuvette, and the flash of light produced from this reaction is
measured as Relative Light Units (RLUs) by the BIO-FLASH
optical system. The RLUs are proportional to the amount
of isoluminol conjugate that is bound to the human IgG,
which is in turn proportional to the amount of autoantibodies
bound to the antigen on the beads.
2.3. BioPlex 2200. BioPlex 2200 (Bio-Rad, Hercules, CA)
system is an automated analyzer that uses multiplex bead
technology (Luminex, Austin, TX, US) to simultaneously
detect antibodies to several antigens in a single tube. The
BioPlex 2200 ANA Screen is intended for the qualitative
screening of ANA, the quantitative detection of antibody
to dsDNA, and the semiquantitative detection of ten sepa-
rate antibodies (Chromatin, Ribosomal P, SS-A, SS-B, Sm,
SmRNP, RNP, Scl-70, Jo-1, and Centromere B) [10, 11] in
human serum and/or EDTA or heparinized plasma. The test
system is used as an aid in the diagnosis of SARD.The system
reports anti-Ro52 and anti-Ro60 antibodies as individual
results outside the United States and the combined result as
anti-SS-A in the United States due to lack of 510 K clearance
by the Food andDrugAdministration (FDA) of the anti-Ro52
antibody assay. Characteristics of the assay are summarized in
Table 1.
2.4. QUANTRIX and Dot Blot. ANA12 IgG BlueDot
(ANA12D+DFS70) and ANA PROFILE 25 Ag DOT (Code:
AD ANA25DBD) for BlueDiver Instrument (both D-tek,
Belgium) were used as comparator methods on discrepant
samples. ANA12 IgG BlueDot contains the antigens:
Nucleosome, Sm, RNP (68 kD/A/C), Ro60, Ro52, SSB(La),
Jo-1, Scl-70, CENP-A/B, PCNA, Ribosome P(P0), and
DFS70. For this study, only anti-Ro60, anti-Ro52, and
anti-SS-B antibodies were used. The test procedure followed
the instruction for use (see http://www.d-tek.be/). ANA
PROFILE 25 Ag DOT contains the antigens: Nucleosome,
dsDNA, Histones, Sm, RNP, Sm/RNP, Ro60, Ro52, SSB(La),
Scl-70, Ku, PM/Scl-100, Mi-2, Jo-1, PL-7, PL-12, SRP,
Ribosome P(P0), CENP-A/B, PCNA, sp100, gp210, M2
recombinant, M2/nPDC, and f-actin. For this study, only
Ro60, Ro52, and SS-B were used.
2.5. Statistical Analyses. The data were statistically evaluated
using the Analyse-it software (Version 1.62; Analyse-it Soft-
ware, Ltd., Leeds, UK). Chi-square, Spearman’s correlation,
and Cohen’s kappa agreement test were carried out to analyze
the agreement between portions, and 𝑃 values < 0.05 were
considered significant. Receiver operating characteristics
(ROC) analysis was used to analyze the discriminatory ability
of different immunoassays. Cluster analysis was used to
illustrate the relationship between different assays [18] and
to display the reactivity pattern of the patients. Hierarchical
clustering was performed using average linkage clustering
where patient correlation was performed uncentered and the
reactivities uncentered.
3. Results
3.1. Correlation between QUANTA Flash and BioPlex 2200.
The overall qualitative agreements between QUANTA Flash
and BioPlex 2200 were 95.4% (95% confidence interval, CI
92.0–97.7%) for anti-Ro52, 98.8% (95% CI 96.4–99.7%) for
anti-Ro60, and 91.7% (95% CI 87.5–94.9%) for anti-SS-B
antibodies (Table 2). Using ROC analyses with the BioPlex
2200 results as the comparator, excellent agreement was
found for anti-Ro60, good for anti-Ro52, and moderate for
anti-SS-B antibodies. Areas under the curve (AUC) values
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Table 1: Sensitivities and specificities of the different assays in different diseases.
QUANTA Flash
Ro52
BioPlex 2200
Ro52
QUANTA Flash
Ro60
BioPlex 2200
Ro60
QUANTA Flash
SS-B
BioPlex 2200
SS-B
Antigen source Recombinant,insect cells
Recombinant,
insect cells
Recombinant,
insect cells Native
Recombinant,
insect cells Native
Analytical
measuring range
(cut-off)
2.3–1685.3 CU
(20CU)
0.2–8.0 units
(1.0 units)
4.9–1374.8 CU
(20CU)
0.2–8.0 units
(1.0 units)
3.3–1706.8 CU
(20CU)
0.2–8.0 units
(1.0 units)
Sensitivity in
SARD % (95% CI) 47.2 (37.5–57.1) 40.7 (31.4–50.6) 65.7 (56.0–74.6) 68.5 (58.9–77.1) 24.1 (16.4–33.3) 33.3 (24.6–43.1)
Sensitivity in SLE
% (95% CI) 50.0 (28.2–71.8) 45.5 (24.4–67.8) 68.2 (45.1–86.1) 68.2 (45.1–86.1) 31.8 (13.9–54.9) 45.5 (24.4–67.8)
Sensitivity in SjS %
(95% CI) 51.9 (37.8–65.7) 44.4 (30.9–58.6) 75.9 (62.4–86.5) 75.9 (62.4–86.5) 31.5 (19.5–45.6) 31.5 (19.5–45.6)
Specificity % (95%
CI) 92.5 (86.6–96.3) 95.5 (90.4–98.3) 93.2 (87.5–96.9) 93.2 (87.5–96.9) 97.7 (93.5–99.5) 94.7 (89.5–97.9)
Table 2: Qualitative agreements between QUANTA Flash and BioPlex assays.
(a)
All patients (𝑛 = 241) BioPlex 2200 Ro52 Percent agreement(95% confidence interval)Positive Negative Total
QUANTA Flash Ro52
Positive 50 11 61 Pos agreement = 100.0% (92.9–100.0%)
Negative 0 180 180 Neg agreement = 94.2% (89.9–97.1%)
Total 50 191 241 Total agreement = 95.4% (92.0–97.7%)
kappa = 0.87 (95% CI 0.80–0.95)
(b)
All patients (𝑛 = 241) BioPlex 2200 Ro60 Percent agreement(95% confidence interval)Positive Negative Total
QUANTA Flash Ro60
Positive 80 0 80 Pos agreement = 96.4% (89.8–99.2%)
Negative 3 158 161 Neg agreement = 100.0% (97.7–100.0%)
Total 83 158 241 Total agreement = 98.8% (96.4–99.7%)
kappa = 0.97 (95% CI 0.94–1.00)
(c)
All patients (𝑛 = 241) BioPlex 2200 SS-B Percent agreement(95% confidence interval)Positive Negative Total
QUANTA Flash SS-B
Positive 26 3 29 Pos agreement = 60.5% (44.4–75.0%)
Negative 17 195 212 Neg agreement = 98.5% (95.6–99.7%)
Total 43 198 241 Total agreement = 91.7% (87.5–94.9%)
kappa = 0.68 (95% CI 0.55–0.81)
were 0.99 for anti-Ro60, 1.00 for anti-Ro52, and 0.88 for anti-
SS-B antibodies (see Figure 1). Additionally good quantitative
agreements were observed. The Spearman rho values were:
0.95 (95% 0.94–0.96) for anti-Ro60, 0.75 (95% 0.69–0.80) for
anti-Ro52, and 0.72 (95% 0.65–0.78) for anti-SS-B antibodies.
3.2. Clinical Performance of QUANTA Flash and BioPlex
2200. The prevalence and titers of anti-Ro52, anti-Ro60,
and anti-SS-B antibodies in different cohorts using both
assay methods can be found in Figure 2. Comparative ROC
analyses were performed on all assays for patients with
SARD compared with controls and showed similar results for
QUANTA Flash and BioPlex 2200 for anti-Ro60 antibodies
(see Figure 3). For anti-Ro52 antibodies the AUC value was
significantly higher for QUANTA Flash compared to BioPlex
2200 (0.82 versus 0.69; 𝑃 < 0.0001). However, the difference
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Table 3: Overview of discrepant samples sorted according to disease state.
Sample ID Diagnosis QUANTRIX(cut-off = 6U/mL) D-tek Dot Blot
QUANTA Flash Ro52
(cut-off = 20CU)
BioPlex 2200 (Ro52)
(cut-off = 1.0)
ASX∼0039 SjS Not tested 1 30.2 0.2
ASX∼0068 SjS 12 1 30.8 0.5
BEx0026 SjS 12 1 25 0.7
BEx0042 SjS 14 1 27.6 0.9
BEx0040 SLE 7 1 24.3 0.2
BEx0046 UCTD 10 1 56.4 0.4
BEx0058 UCTD 0 0 21.4 0.2
ASX∼0088 RA 40 1 254.9 0.2
BSX0053 RA Not tested 1 200.2 0.2
BSX0056 RA Not tested 1 55.6 0.2
BSX0035 AT Not tested 0 69.2 0.2
Sample ID Diagnosis QUANTRIX(cut-off = 6U/mL) D-tek Dot Blot
QUANTA Flash Ro60
(cut-off = 20CU)
BioPlex 2200 (Ro60)
(cut-off = 1.0)
BEx0006 UCTD Not tested 0 4.9 8
BEx0051 UCTD 0 0 4.9 1.2
BEx0056 UCTD 0 0 8.2 1.1
Sample ID Diagnosis QUANTRIX(cut-off = 6U/mL) D-tek Dot Blot
QUANTA Flash SSB
(cut-off = 20CU)
BioPlex 2200 (SSB)
(cut-off = 1.0)
BEx0001 SjS 0 0 8.4 3
BEx0014 SjS 0 0 24.8 0.9
BEx0035 SjS 0 0 13.1 8
BEx0036 SjS Not tested Not tested 25.5 0.2
ASX∼0076 SLE 0 0 16.6 8
ASX∼0082 SLE 0 0 8.5 8
BEx0054 SLE 0 0 3.3 1
BEx0013 UCTD Not tested 0 4.2 8
BEx0022 UCTD 0 0 3.3 1.2
BEx0030 UCTD Not tested 0 3.3 8
BEx0033 UCTD Not tested 1 225.8 0.2
BEx0037 UCTD 0 0 5.3 1.9
BEx0058 UCTD 0 0 5.5 1.2
BEx0067 UCTD 0 0 5.1 4.7
BEx0068 UCTD 0 0 3.3 1.8
BEx0069 UCTD 0 0 3.3 2.7
ASX∼0098 RA 0 0 3.3 1.2
BEx0060 RA 0 0 16 2.4
BSX0043 RA 0 0 3.3 4.2
BSX0091 HI 0 0 3.3 1.1
AT: atopic dermatitis; HI: healthy individual; UCTD: undifferentiated connective tissue disease; RA: rheumatoid arthritis; SjS: Sjo¨gren syndrome; SLE: systemic
lupus erythematosus.
was found in the nonclinically relevant area of the AUC. For
anti-SS-B antibodies the AUC value was slightly higher for
QUANTA Flash compared to BioPlex 2200 (0.73 versus 0.69;
𝑃 > 0.05). The sensitivities and specificities among SARD,
SLE, and SjS patients are shown in Table 1.
3.3. Analysis of Discrepant Samples. Discrepant samples (20
anti-SS-B, 11 anti-Ro52, 3 anti-Ro60) with sufficient residual
volume (𝑛 = 33) were tested by two comparative methods.
Thirty out of 33 discrepant samples among all assays (19 anti-
SS-B, 11 anti-Ro52, 3 anti-Ro60) retested by D-tek dot blot
agreed with the QUANTA Flash results (Table 3). Five of the
20 anti-SS-B discrepant samples were high positive on Bio-
Plex (>8.0 units, above the AMR) and negative on QUANTA
Flash, BlueDot, and QUANTRIX. Of the 17 BioPlex anti-
SS-B positive/QUANTA Flash anti-SS-B negative samples 14
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Figure 1: Comparison of QUANTA Flash with BioPlex 2200 as comparative method. Receiver operating characteristic (ROC) curves are
shown in (a)–(c) and Spearman’s correlation diagrams in (d)–(f). Note: A significant portion of positive samples are above the analytical
measuring range of BioPlex which biases the Spearman rho values. PPA/NPA/TPA: Positive/Negative/Total % agreement. AUC: area under
the curve.
were from SARD and 4 from non-SARD patients (3 RA and
oneHI). All threeQUANTAFlash anti-SS-B positive/BioPlex
anti-SS-B negative samples were from SARD patients. All
three were additionally anti-Ro60 antibody positive by both
methods (QUANTA Flash and BioPlex). Figure 4 depicts
a cluster analysis of all methods sorted by disease group,
which serves as a visual aid of the antibody prevalence and
differences between methods.
3.4. Effect of Multiple Positivity and Titer on Likelihood
of Disease. To analyze the clinical utility of autoantibody
titer and multiple positivity as previously described [16], we
analyzed (a) the performance characteristics at the cut-off
corresponding to the highest LR+ in comparison with the
recommended cut-off and (b) multiple positivity (Table 4).
Double positivity provided the highest LR+ for SARD com-
pared to the controls (both for BIO-FLASH and BioPlex
2200). Highest LR+ (12.31/16.3) was obtained with SS-B at a
low cut-off of 6.3 CU (QUANTA Flash)/4.3 units (BioPlex).
4. Discussion
The detection of anti-ENA antibodies is important to help in
the diagnosis of SARD [1]. In recent years, several new and
automated methods for the detection of anti-ENA antibodies
have been developed [10, 11, 14, 15]. However, the standard-
ization of antibody assays is still not nearly accomplished,
and significant variations between different assays have been
reported [19]. Since reliable detection of autoantibodies is
of high importance, careful verification and validation of
the assay performance is mandatory. Since the prevalence
of antibodies to the other antigens contained in the BioPlex
2200 ANA profile was low and did not allow for statistical
evaluation,we focused on the comparison betweenQUANTA
Flash and BioPlex 2200 assays for the detection of anti-Ro52,
anti-Ro60, and anti-SS-B antibodies.
A broad range of line immunoassays (LIA) and dot-
blot assays are available and are usually used to confirm
previous identified autoantibodies [20, 21]. Mainly manually
performed, these assays offer a simple way of multiplex
testing and even automated LIAs have become available [8].
Therefore, we choose a Dot blot assay (variation of LIA)
and a microarray as confirmation assays for the discrepant
samples. Multiplex assays based on the Luminex technology
use addressable laser beads and are therefore often referred
to as ALBIA (addressable laser bead assays) or multiplex flow
immunoassay (MFI) [9]. Today several commercial MFI kits
are available for the detection of autoantibodies to nuclear
antigens [10, 11, 22, 23]. Similar to LIAs, the number of
antigens and the antigen composition significantly varies.
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Figure 2: Prevalence and titers of anti-Ro60, Ro52, and SS-B antibodies. Results for anti-Ro60 are shown in (a) and (b), for anti-Ro52 in (c)
and (d), and for anti-SS-B antibodies in (e) and (f). AT: Atopic dermatitis, HI: healthy individuals, RA: rheumatoid arthritis, SED: suspected
eye disease, SLE: systemic lupus erythematosus, SjS: Sjo¨gren’s syndrome, SSc: systemic sclerosis, UCTD: undifferentiated connective tissue
disease.
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Figure 3: Clinical comparative ROC analysis. Results of patients with systemic autoimmune rheumatic diseases were comparedwith controls.
Cut-off values are indicated by arrows. For sensitivity and specificity, see Table 1. Results for anti-Ro60 (a), anti-Ro52 (b), and anti-SS-B
antibodies (c) are shown.
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Figure 4: Supervised cluster analysis of the results. Supervised centered cluster analysis according to disease cohort is shown.Thedendrogram
shows that the Ro60 assays are closely related, the Ro52 assays are somewhat related, and the SS-B assays show significant difference. AT: atopic
dermatitis; UCTD: undifferentiated connective tissue disease, RA: rheumatoid arthritis, SSc: systemic sclerosis; SED: suspected eye disease,
SLE: systemic lupus erythematosus; HI: healthy individuals; SARD: systemic autoimmune rheumatic disease.
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Table 4: Multiple positivity for Ro60, Ro52, and SS-B.
BIO-FLASH Singlepositive
Double
positive
Triple
positive Ro60 > 110 CU SS-B > 6.3 CU SS-B > 482CU
Sensitivity 75.9% 39.8% 21.3% 58.3% 37.0% 25.0%
Specificity 89.5% 96.2% 97.7% 94.7% 97.0% 97.0%
Likelihood ratio (+) 7.21 10.59 9.44 11.08 12.31 8.31
Likelihood ratio (−) 0.27 0.63 0.81 0.44 0.65 0.77
BioPlex 2200 Singlepositive
Double
positive
Triple
positive Ro60 > 2.2 units SS-B > 4.3 units SS-B > 0.4 units
Sensitivity 80.6% 38.9% 21.3% 27.8% 25.0% 45.4%
Specificity 90.2% 96.2% 97.0% 96.2% 98.5% 95.5%
Likelihood ratio (+) 8.24 10.34 7.08 7.39 16.63 10.06
Likelihood ratio (−) 0.22 0.63 0.81 0.75 0.76 0.57
First generationMFI showed polyreactivitywhichwas caused
by unspecific binding to the beads. Second generation showed
significant reduced polyreactivity and thus higher specificity
[24]. Multiplex assays are commonly used as a screening
test for ANA or other autoantibodies. Additional methods
have been developed for automated ANA detection [25–27].
Several publications have described protein arrays for the
detection of autoantibodies to nuclear antigens [13].However,
until today those assays are not widely used in routine
laboratories. The microarray used in this study showed
good agreement with other methods and might represent a
promising multiplex platform for autoantibody detection.
Although the QUANTA Flash and BioPlex 2200 use
different sources of antigens (recombinant versus native for
Ro60), the results are very similar. During the last decade,
significant improvements have been made in recombinant
protein technology [28]. In particular, novel strategies for
the generation of recombinant Ro60 led to the availability
of this antigen as a high quality recombinant protein [4].
Recombinant antigen manufacturing is more consistent and
less dependent on the biological variations of the source
material [28]. Therefore, the novel CIA shows similar assay
performance combined with high degree of precision and
consistency [15]. Despite the fact that both systems use
recombinant Ro52 antigen, differences in the results were
observed. Therefore, the difference might be related to the
different antigen immobilization (bead chemistry) between
the QUANTA Flash and the BioPlex 2200 system. However,
our total percent agreement (95.4%, Table 2) is significantly
better than agreements previously reported [5]. One putative
reason for the significant difference between the QUANTA
Flash and BioPlex 2200 results for anti-SS-B antibodies is
the antigen source. The QUANTA Flash SS-B assay utilizes
recombinant SS-B expressed in insect cells, whereas the
BioPlex 2200 is based on native SS-B antigen [15]. Retesting of
the discrepant samples using two additional methods mostly
confirmed the QUANTA Flash results.
It is also important to point out that 5/17 BioPlex 2200
anti-SS-B positive samples (range 1–1.2 units) and 2/3 anti-
SS-B positive samples by QUANTA Flash (range 20–25CU)
were low positive. Therefore, it is possible that a modified
cut-off value would increase the agreement between BioPlex
2200 and QUANTA Flash SS-B. In the case of anti-SS-B
discrepant samples, 16/20 are from SARD and 4 from “non-
SARD” patients (3 RA and 1 HI). It is relevant that 3/4 “non-
SARD” but only 3/16 of the SARD patients are only anti-
SS-B positive. Since anti-SS-B antibodies occur in different
SARD and no “gold standard” is available for the detection of
anti-SS-B antibodies, it remains speculative which results are
clinically correct and meaningful.
When compared to previous studies which analyzed the
performance of the BioPlex 2200 system [10, 11], our datawere
in general agreement with the published data. In a large study
on 510 healthy individuals, 0.2% (anti-Ro52), 0.6% (anti-
Ro60), and 0.8% (anti-SS-B) were positive [10]. Despite the
small number of HI used in our study, our data confirmed
the specificity against HI. In a second study, the prevalence
of antibodies to Ro52, Ro60, and SS-B was described [16].
Overall, the results were in agreement or not significant due
to small patient groups. The QUANTA Flash assays have
just been launched, and therefore only one paper has been
published [16].
Historically autoantibody test results weremostly consid-
ered individually. Recently, several studies reported increased
utility by combining autoantibody assay results and by con-
sidering antibody titers [16]. Consequently, we strived to ana-
lyze the synergy effect of combining the results of antibody
testing for anti-Ro52, anti-Ro60, and anti-SS-B antibodies.
Additionally, we analyze the impact of the antibody titers
on the likelihood of disease. Although we found increased
performance characteristics when combining results and
with optimized cut-off values, the incremental value was not
as pronounced as previously reported [16]. This might be
explained by the strong overlap between the three antibodies
we studied.
5. Conclusion
QUANTA Flash and BioPlex 2200 show good qualita-
tive agreement. The clinical performances were similar for
anti-Ro52 and Ro60 autoantibodies while differences were
observed for anti-SSB (La) antibodies.
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Highlights
(i) Good agreements between QUANTA Flash and Bio-
Plex 2200 were found for anti-Ro52 and anti-Ro60.
(ii) Retesting of discrepant samples confirm in themajor-
ity of cases the QUANTA Flash results.
(iii) Antibody titer and multiple positivity might provide
additional value for anti-ENA testing.
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